Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by John O. Mascarenhas
Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
Related publications
Ruxolitinib as an Emerging Treatment in Myelofibrosis
Blood and Lymphatic Cancer: Targets and Therapy
Definition and Management of Ruxolitinib Treatment Failure in Myelofibrosis
Blood Cancer Journal
Oncology
Hematology
Safety and Efficacy of Ruxolitinib in Myelofibrosis Patients Without Splenomegaly
British Journal of Haematology
Hematology
Ruxolitinib for Myelofibrosis–An Update of Its Clinical Effects
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients With Intermediate and High-Risk Myelofibrosis
Clinical Cancer Research
Cancer Research
Oncology
Efficacy of Ruxolitinib for Myelofibrosis
Expert Opinion on Pharmacotherapy
Medicine
Pharmacology
Cost-Effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain
Journal of Health Economics and Outcomes Research
Sustained-Release Ruxolitinib: Findings From a Phase 1 Study in Healthy Subjects and a Phase 2 Study in Patients With Myelofibrosis
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
JAK Inhibition With Ruxolitinib Versus Best Available Therapy for Myelofibrosis
New England Journal of Medicine
Medicine